Design Principles for Maximising the Drug Delivery Efficiency & Therapeutic Index of ADCs, Presented by Seattle Genetics, at SMi’s ADC Conference
London, United Kingdom, January 25, 2018 --(PR.com)-- Join a huge community of ADC specialists at the Antibodies & Antibody Drug Conjugates conference this April 9th - 10th, Copthorne Tara Hotel, London. Now in its 6th year with a global presence, join a room full of scientists from Spirogen, Pfizer, Genentech, Ablynx, Seattle Genetics, Janssen, MedImmune and more.
Seattle Genetics will be presenting their acumen into "Design Principles for Maximising the Drug Delivery Efficiency & Therapeutic Index of ADCs."
The conjugation of drug-linkers to an antibody can result in increased nonspecific uptake and catabolism in healthy tissues. This phenomenon has two potential negative consequences - unintended delivery of the drug to non-target tissues, and diminished exposure of the tumor to the ADC, however, careful design of the drug-linker can minimize this effect in preclinical models, with demonstrable decreases in drug concentrations in normal tissues paired with maximal delivery to the tumor. Toxicology and xenograft studies indicate that the optimized design both decreases off-target toxicity and improves antitumor activity, and they are currently planning to evaluate this design clinically with an anti-CD48 antibody for patients with multiple myeloma.
This will be presented by Robert Lyon, Senior Director Protein Sciences, Seattle Genetics Ltd, on Day 2 @ 11:40.
Download a brochure online for more info: www.adcsummit.com/prc
About Robert:
Robert Lyon received in PhD in Medicinal Chemistry from the University of Washington in 2002. Since joining Seattle Genetics in 2005, he has made numerous contributions to the field of antibody-drug conjugates, with a particular emphasis on understanding and improving ADC disposition. Dr. Lyon is currently a Senior Director in the Protein Sciences Department, where he continues to lead efforts to innovate optimal ADC technologies.
Further information is available at: www.adcsummit.com/prc
SMi presents the 6th Annual Conference:
ADC Summit
Date: 9th – 10th April 2018
Location: Copthorne Tara Hotel, London UK
Website: www.adcsummit.com/prc
Contact Information:
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Seattle Genetics will be presenting their acumen into "Design Principles for Maximising the Drug Delivery Efficiency & Therapeutic Index of ADCs."
The conjugation of drug-linkers to an antibody can result in increased nonspecific uptake and catabolism in healthy tissues. This phenomenon has two potential negative consequences - unintended delivery of the drug to non-target tissues, and diminished exposure of the tumor to the ADC, however, careful design of the drug-linker can minimize this effect in preclinical models, with demonstrable decreases in drug concentrations in normal tissues paired with maximal delivery to the tumor. Toxicology and xenograft studies indicate that the optimized design both decreases off-target toxicity and improves antitumor activity, and they are currently planning to evaluate this design clinically with an anti-CD48 antibody for patients with multiple myeloma.
This will be presented by Robert Lyon, Senior Director Protein Sciences, Seattle Genetics Ltd, on Day 2 @ 11:40.
Download a brochure online for more info: www.adcsummit.com/prc
About Robert:
Robert Lyon received in PhD in Medicinal Chemistry from the University of Washington in 2002. Since joining Seattle Genetics in 2005, he has made numerous contributions to the field of antibody-drug conjugates, with a particular emphasis on understanding and improving ADC disposition. Dr. Lyon is currently a Senior Director in the Protein Sciences Department, where he continues to lead efforts to innovate optimal ADC technologies.
Further information is available at: www.adcsummit.com/prc
SMi presents the 6th Annual Conference:
ADC Summit
Date: 9th – 10th April 2018
Location: Copthorne Tara Hotel, London UK
Website: www.adcsummit.com/prc
Contact Information:
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Pav Solanki
+44 (0) 207 827 6048
www.adcsummit.com/prc
Pav Solanki
+44 (0) 207 827 6048
www.adcsummit.com/prc
Contact
Categories